Together with Medicare reimbursement, we estimate that the total number of covered lives for which our Cancer Origin Test could be adjudicated as ‘in-network’ exceeds 170 million,” said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
Source: www.topix.com Via newsmixx: home News